title: Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.
abstract: Advances in the molecular characterization of human tumors have led to increased interest in the development of targeted therapeutics to include cancer vaccines. The recent success of sipuleucel-T, an autologous cellular vaccine administered to patients with hormone-refractory metastatic prostate cancer, suggests that this is a viable therapeutic option in the management of patients with solid tumors. This article focuses on breast cancer vaccines emphasizing delivery platforms, target antigens and novel strategies designed to enhance response to vaccination that are being evaluated in ongoing Phase II clinical trials.
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Mittendorf
authors.forename: Gheath
authors.initials: G
authors.lastname: Alatrash
authors.forename: Haile
authors.initials: H
authors.lastname: Xiao
authors.forename: G Travis
authors.initials: GT
authors.lastname: Clifton
authors.forename: James L
authors.initials: JL
authors.lastname: Murray
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
mesh_terms: D001943:Breast Neoplasms / Q000276:immunology* / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D054547:National Cancer Institute (U.S.); D016896:Treatment Outcome; D014481:United States
chemical_list: D019496:Cancer Vaccines